Studies on the metabolism of isopnosphamide (NSC-109724) in man
- PMID: 1277219
Studies on the metabolism of isopnosphamide (NSC-109724) in man
Abstract
A method is described for the quantitative determination of cyclophosphamide, isophosphamide, and trophosphamide and their stable alkylating metabolites on thin-layer chromatography plates with the aid of 4-pyridinealdehydr-2-benzothiazolylhydrazone (PBH). The method requires only 0.01-0.02 ml of urine from patients treated with high doses of cyclophosphamide of isophosphamide, but a careful standarization is required by using reference substances. In the urine of patients treated with isophosphamide, the 4-carboxy derivative and two different dechloroethyl derivatives resulting from side-chain oxidation are the predominant metabolites determined, next to isophosphamide. Side-chain oxidation may be prevalent. Determination of isophosphamide and its stable alkylating metabolites in the urine of 25 patients shows that the ratio of unchanged isophosphamide to its metabolites varies widely. The mean value of the total amount of PBH-reactive compounds exceeded 50% of the given dose, whereas less than 1% was found to be converted to urine metabolites which release acrolein.
Similar articles
-
[Quantitative determination of cyclophosphamide, ifosfamide, and trofosfamide and their stable metabolites on TLC-plates with the aid of 4-pyridine-aldehyde-2-benzothiazolyl-hydrazone (PBH) (author's transl)].Arzneimittelforschung. 1975 Sep;25(9):1331-6. Arzneimittelforschung. 1975. PMID: 1242654 German.
-
Studies on the human pharmacokinetics of isophosphamide (NSC-109724).Cancer Treat Rep. 1976 Apr;60(4):451-8. Cancer Treat Rep. 1976. PMID: 1277221
-
Side chain oxidation of ifosfamide in man.Klin Wochenschr. 1975 Nov 15;53(22):1075-6. doi: 10.1007/BF01614384. Klin Wochenschr. 1975. PMID: 1226040
-
The analysis of ifosfamide and its metabolites (review).Anticancer Res. 1993 Sep-Oct;13(5A):1311-24. Anticancer Res. 1993. PMID: 8239501 Review.
-
The comparative pharmacology of cyclophosphamide and ifosfamide.Semin Oncol. 1982 Dec;9(4 Suppl 1):2-7. Semin Oncol. 1982. PMID: 6761865 Review. No abstract available.
Cited by
-
Clinical pharmacokinetics of N-acetylcysteine.Clin Pharmacokinet. 1991 Feb;20(2):123-34. doi: 10.2165/00003088-199120020-00004. Clin Pharmacokinet. 1991. PMID: 2029805 Review.
-
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.Cancer Chemother Pharmacol. 1988;22(4):321-4. doi: 10.1007/BF00254239. Cancer Chemother Pharmacol. 1988. PMID: 3168145
-
Metabolism and pharmacokinetics of oral and intravenous ifosfamide.J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S148-53. doi: 10.1007/BF01613221. J Cancer Res Clin Oncol. 1991. PMID: 1795004 Free PMC article. Clinical Trial.
-
Ifosfamide nephrotoxicity in adult patients.Clin Kidney J. 2019 Dec 31;13(4):660-665. doi: 10.1093/ckj/sfz183. eCollection 2020 Aug. Clin Kidney J. 2019. PMID: 32897279 Free PMC article.
-
Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.J Cancer Res Clin Oncol. 1987;113(2):160-5. doi: 10.1007/BF00391439. J Cancer Res Clin Oncol. 1987. PMID: 3104347 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources